[ad_1]
Vltava Fund, an funding administration firm, not too long ago launched its third-quarter 2025 investor letter. A duplicate of the letter may be downloaded right here. The letter is addressed “Worth Traps and Development Traps,” primarily based on the agency’s three new investments from the final quarter. Whereas worth and development shares seem to be clear classes, the creator believes they’re interconnected relatively than opposites. A worth entice happens when buyers purchase seemingly low-cost shares with underlying structural points, leading to stagnation or a decline in share value. Nevertheless, a development entice arises when buyers buy shares of quickly rising corporations with excessive valuations that unexpectedly decelerate, resulting in diminished projections and declining valuation multiples. Principally, each worth and development are two sides of a coin, and the investor ought to mix an inexpensive value with a practical outlook. As well as, please verify the fund’s high 5 holdings to know its finest picks in 2025.
In its third-quarter 2025 investor letter, Vltava Fund highlighted shares similar to Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages within the analysis and improvement, manufacture, and distribution of pharmaceutical merchandise. The one-month return of Novo Nordisk A/S (NYSE:NVO) was -7.97%, and its shares misplaced 48.20% of their worth during the last 52 weeks. On October 3, 2025, Novo Nordisk A/S (NYSE:NVO) inventory closed at $59.63 per share, with a market capitalization of $263.101 billion.
Vltava Fund said the next relating to Novo Nordisk A/S (NYSE:NVO) in its third quarter 2025 investor letter:
“Novo Nordisk A/S (NYSE:NVO) most likely wants no lengthy introduction. It’s one in every of Europe’s largest corporations and a world chief within the remedy of two main life-style illnesses – diabetes and weight problems. The corporate has grown traditionally by way of the event and manufacturing of insulin and has held a dominant share of the worldwide market in that group of merchandise for many years. In recent times, weight problems remedy has change into its key development section. Its best-known product is Wegovy, which has confirmed to be extremely efficient in weight discount. A smaller a part of the enterprise consists of medicine for uncommon illnesses, notably within the areas of hemophilia and development hormone remedy. Novo Nordisk has extremely built-in manufacturing, from molecule improvement to completely automated filling strains for injection pens, and world distribution to greater than 170 nations, with a deal with america, Europe, and a quickly rising share in Asia. Its largest competitor is Eli Lilly, and these two corporations now successfully type a duopoly in fashionable remedy of diabetes and weight problems. Boundaries to entry into the business are extraordinarily excessive, as a consequence of lengthy improvement instances, regulation, and large investments in manufacturing and distribution.
[ad_2]
